This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that ...

This study represents the first real-time, continuous blood glucose monitor (CBGM ... While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed ...

The company also appointed Ted Williams as Vice President of Regulatory Affairs to advance their continuous blood glucose monitoring system. Glucotrack issued 134.78 million shares of common stock ...

This innovative CBGM system, designed for continuous, accurate glucose monitoring over three years without any on-body external component, offers a more convenient and less intrusive alternative ...

implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense ® 365 CGM system. Eversense 365 is the ...

Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time, ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...